Dean Li invites another under-the-radar biotech to Merck's dealmaking table as Amathus signs neurodegeneration pact
Less than three months since taking over from Roger Perlmutter, new Merck R&D chief Dean Li continues to wheel and deal.
Li and the Merck team have agreed to a new collaboration with little-known biotech Amathus Therapeutics, promising an undisclosed upfront amount in addition to an option to acquire the company. Should the option be exercised, Amathus would be in line for up to $500 million in milestones per program.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.